Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Farrow, I. Uings, M. Haase, D. Angell, K. leavens, J. Holt, J. matthews, K. biggadike, D. needham (Stevenage, United Kingdom). LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile. Eur Respir J 2013; 42: Suppl. 57, 1968

Member's Comments

No comment yet.

Related content which might interest you: The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Decoy chemokine neutraligands with anti-asthmatic activity Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 LATE-BREAKING ABSTRACT: T-cell membrane organization as a potential new target in asthma Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Dehydroepiandrosterone in the treatment of steroid resistant asthma: Whether synthetic nanoform can replace the natural hormone? Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014